Rankings
▼
Calendar
▼
FLNA FY 2024 Earnings Report — Filana Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Filana Therapeutics, Inc.
FLNA
FY 2024 Earnings
Reported December 31, 2024
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
FY 2024
Prior Q
FY 2023
QoQ Change
YoY Change
Revenue
$0
—
$0
—
—
Op. Income
-$141M
—
-$106M
—
-33.5%
EPS (Diluted)
$-1.46
—
$-2.32
—
37.1%
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$70M
Selling & Marketing
$0
General & Administrative
$72M
SG&A Expenses
$72M
Other Expenses
$0
Operating Expenses
$141M
Cost & Expenses
$141M
OPERATING INCOME
-$141M
Interest Income
$9M
Interest Expense
$0
Other Income/Expenses
$117M
INCOME BEFORE TAX
-$24M
Income Tax Expense
$0
Net Income from Continuing Ops
-$24M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$24M
Net Income Deductions
$44M
BOTTOM LINE NET INCOME
-$68M
D&A
$1M
EBIT
-$142M
EBITDA
-$141M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
← FY 2023
FLNA Overview
Q3 2024 →